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Efficacy of Endobronchial Ultrasound-Guided
Transbronchial Needle Aspiration of Hilar Lymph Nodes for
Diagnosing and Staging Cancer
Armin Ernst, MD,*† Ralf Eberhardt, MD,* Mark Krasnik, MD,‡ and Felix J. F. Herth, MD†
Introduction: Endobronchial ultrasound-guided transbronchial nee-
dle aspiration (EBUS-TBNA) is used mostly in patients with non-
small cell lung cancer (NSCLC) to sample mediastinal lymph nodes
that are visible on computed tomography (CT). We sought to
determine the efficacy of EBUS-TBNA in sampling enlarged hilar
lymph nodes in this patient population.
Methods: From January 2004 to May 2007, patients with suspected
NSCLC and CT or positron emission tomography (PET) imaging
demonstrating enlarged (1 cm) or PET-positive hilar lymph nodes
underwent EBUS-TBNA. Patients with enlarged central mediastinal
nodes were excluded. Identifiable lymph nodes at locations 10R,
10L, 11R, and 11L were aspirated. All patients underwent subse-
quent surgical staging or clinical follow-up as indicated. Diagnoses
based on aspirates were compared with those based on surgical or
clinical results.
Results: Of 213 patients evaluated (mean age, 56 years; 138 men),
188 (mean age, 56.3 years; 120 men) were diagnosed with NSCLC
and were analyzed. In these patients, 229 lymph nodes, ranging 8 to
20 mm, were detected, and all were sampled. Of the 188 patients, 25
had a single enlarged node in a contralateral hilar position (N3), 40
had multiple enlarged ipsilateral nodes in the N1 position, and 123
had an ipsilateral single enlarged node in the N1 position. Overall,
diagnostic sensitivity of EBUS-TBNA was 91%, specificity was
100%, and the positive predictive value was 92.4%. In the 25
patients with contralateral hilar nodes, sensitivity was 66%, speci-
ficity was 100%, and the positive predictive value was 96%.
Conclusions: No complications occurred. In experienced hands,
EBUS-TBNA of enlarged hilar lymph visible on CT or hilar nodes
that are PET scan-positive can provide diagnostic results similar to
those for central mediastinal nodes.
Key Words: Endobronchial ultrasound, Lung cancer, Mediastinal
lymphadenopathy, Hilar staging, Transbronchial needle aspiration.
(J Thorac Oncol. 2009;4: 947–950)
Correct staging of patients with non-small cell lung cancer(NSCLC) provides accurate information on the extent of
disease and guides the choice of treatment. It is also funda-
mental for estimating prognosis and for comparing studies of
treatments and survival. When there are no distant metasta-
ses, mediastinal lymph node involvement is the most impor-
tant prognostic factor in patients with NSCLC, and the nature
of this involvement influences therapeutic strategies.1,2
Since the tumor, node, metastasis lung cancer staging
system was developed in 1968,3 lymph node involvement has
been categorized as N0 (no nodes involved), N1 (peribron-
chial, interlobar, or perihilar lymph nodes involved), N2
(ipsilateral mediastinal nodes involved), or N3 (contralateral
mediastinal or supraclavicular nodes involved). The classifi-
cation of these N descriptors into the overall tumor stages of
I to III has been used to predict outcomes and to assist in
treatment selection.4
The most recent report of the International Association
for the Study of Lung Cancer analyzed more than 67,000
patients. In the report, among patients undergoing resection
without induction therapy, Rusch et al.5 identified three dis-
tinct prognostic groups: (1) patients with a single node in
zone N1, (2) patients with multiple nodes in zone N1 or with
a single node in zone N2, and (3) patients with multiple nodes
in zone N2. Therefore, not only is the staging of central
mediastinal lymph nodes important, but also the proper as-
sessment of nodes in the hilar region before making definitive
therapeutic decisions.
Hilar lymph nodes can be staged with noninvasive (e.g.,
imaging) and invasive (sampling) procedures. Computed to-
mography (CT), magnetic resonance imaging, positron emission
tomography (PET), and PET-CT are used for noninvasive
imaging.6–9 Despite advances in the latest imaging techniques
and although they can identify nodes suspicious for malig-
nancy, they provide only a clinical stage or diagnosis; inva-
sive procedures and cytologic or histologic confirmation of
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biopsy samples (invasive staging) is still required to clarify
the pathologic stage.(1–11)
Invasive staging of the hilar regions can be performed by
video-assisted thoracoscopic surgery or open surgery.10 Invasive
staging can also be performed with needle biopsy techniques
including transbronchial needle aspiration (TBNA), endo-
scopic ultrasound-guided fine-needle aspiration, and, most
recently, endobronchial ultrasound-guided (EBUS-TBNA).12
Because of the anatomic location of hilar nodes, a
reliable bronchoscopic staging approach may be superior
in ease and complication rate when compared with other
modalities.
The aim of this study was to evaluate the value of
EBUS-TBNA in obtaining samples for staging hilar lymph
nodes ipsilateral and contralateral to the primary lesion.
PATIENTS AND METHODS
Approval from the local institutional review board was
obtained. From January 2004 to May 2007, all patients with
lung masses suspicious for NSCLC and lymphadenopathy
limited to a hilum were evaluated for inclusion in this
prosepective study. All patients were presented in multidis-
ciplinary Tumor boards, and a chest radiograph and CT scan
of the chest (plain and contrast enhanced) were performed in all
patients; PET scans were obtained on an individual basis based
on clinical assessment. Patients with mediastinal lymphade-
nopathy or extrathoracic disease were excluded from the
study, as well as the patients with comorbidities which did
not allow for safe bronchoscopy. Written informed consent
was obtained from all patients included in the study.
If the patient had never undergone bronchoscopy, con-
ventional flexible bronchoscopy (model BF-160/T-180 bron-
choscope; Olympus Ltd, Tokyo, Japan) was first performed to
examine the tracheobronchial tree, followed by an EBUS
examination with a dedicated EBUS-TBNA bronchoscope
(model BF-UC260F-OL8; Olympus). If the patient had al-
ready undergone videobronchoscopy, the EBUS examination
was performed directly. Bronchoscopy procedures were per-
formed with the patient receiving local anesthesia and mod-
erate sedation (midazolam) or general anesthesia.
Transbronchial Needle Aspiration
The EBUS-TBNA examination was performed with a
flexible ultrasonic puncture bronchoscope with a linear scan-
ning transducer according to a standard protocol as described
previously and as an outpatient procedure.12,13 The ultrasound
transducer scans parallel to the insertion direction of the
bronchoscope and is connected to a dedicated ultrasound
scanner (EU-C60; Olympus Ltd, or Prosound alpha 5, Aloka,
Japan) with Doppler-flow imaging to detect blood vessels.
The endoscope was passed through the mouth and
vocal cords to the main carina, then to the distal left and right
bronchi. Regional hilar lymph node stations (stations 10 and
11) were imaged systematically during slow withdrawal and
rotation of the transducer (Figures 1, 2). Enlarged nodes were
aspirated twice (Figure 3). Rapid on-site pathologic evalua-
tion was not used. The aspirates were placed onto at least four
glass slides, air dried, treated with Papanicolaou stain, and
assessed by a cytopathologist.
FIGURE 1. Single lymph node in the 11L position.
FIGURE 2. Two lymph nodes in the 11R position. The
lymph node capsule are clearly visible because it is a small
vessel.
FIGURE 3. Needle entry into a single lymph node in the
11L position.
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Establishing the Reference Diagnoses
The definitive diagnosis was made by biopsy of the
primary parenchymal tumor and, the final pathologic staging
was determined during subsequent thoracotomy, thoracos-
copy, or during clinical follow-up for 6 months. Diagnoses
based on real-time EBUS-TBNA were compared with those
based on open thoracotomy, thoracoscopy, or clinical follow-
up. A positive cytologic result of malignancy was accepted as
evidence of cancer, and the patients were treated accordingly.
Statistical Methods
Diagnostic sensitivity, specificity, and accuracy were
calculated using the standard definitions. Alpha was set at
0.05, and the SPSS 11.5 (SPSS Inc., Chicago, IL) statistical
software package was used for all analyses.
RESULTS
From January 2004 to May 2007, 213 patients (mean
age, 56 years; 138 men) were identified as having parenchy-
mal lesions highly suspicious for NSCLC and enlarged or
PET-positive hilar nodes only. A positive diagnosis of
NSCLC based on open thoracotomy, thoracoscopy, or clini-
cal follow-up was established in 188 patients (mean age, 56.3
years; 120 men). Of the 25 patients with other diagnoses, 12
had small cell lung cancer, five had sarcoidosis, and two of
each had tuberculosis, cryptogenic organizing pneumonia, or
distant metastasis (Table 1). Two patients refused surgery.
Moderate sedation was used for the procedure in 133 patients
(90 men) and general anesthesia in 55 patients (30 men). In
the analyzed 188 patients, samples were obtained from all
229 identified enlarged or PET-positive lymph nodes (range,
8–20 mm; median, 15.6 mm; interquartile range, 0.36). The
locations of these nodes were as follows: 25 patients (13%)
had a single enlarged node in a contralateral hilar position of
which 12 were PET positive. Forty (21%) had multiple
enlarged nodes in the N1 position, and 123 (66%) had a
single enlarged node in the N1 position.
Of the 163 patients with nodes in the ipsilateral hilar
position, 123 had a single enlarged station, and 40 had two
enlarged N1 station (e.g., 10R and 11R). Malignancy was
confirmed to be present in 117 patients.
In the 25 patients with enlarged nodes in the contralat-
eral hilar position 3 (12%) proved to be malignant.
Cancer was staged correctly by EBUS-TBNA in 174 of
the 188 patients (93%). Surgery or clinical follow-up identi-
fied lymph node metastasis in the remaining 14 patients: 11
had a single ipsilateral node, two had two ipsilateral nodes,
and one had a contralateral hilar node. Possible reasons for
unsuccessful endobronchial staging in these patients include
the lack of lymphocytes in the aspirate (seven patients), too
much blood in the aspirate for analysis (four cases), and not
sampling the correct node (two patients). The reason is
unknown in one patient.
Endoscopic staging was correct in 112 of 123 patients
(91%) with a single hilar node, in 38 of 40 patients (95%)
with a double ipsilateral nodes, and in 24 of 25 patients (96%)
with a contralateral hilar node.
Overall, sensitivity was 91%, specificity was 100%,
and the positive predictive value was 92.4%. For the 25
patients with contralateral hilar nodes, sensitivity was 66%,
specificity 100%, and positive predictive value was 96%.
Patients with single or double hilar nodes did not differ
significantly (p  0.7).
No complications occurred during any procedure.
DISCUSSION
In this trial, we showed that EBUS-TBNA performed
very well when used to biopsy enlarged or PET-positive hilar
lymph nodes and that it identified malignant hilar lymph
nodes with the same accuracy as it detects malignant central
mediastinal nodes. The 91% sensitivity, 100% specificity,
and 92.4% positive predictive value are virtually the same
performance characteristics as reported for mediastinal
nodes.12–16 In a recent multicenter study, we reported on the
effectiveness and accuracy of EBUS-TBNA for evaluating
mediastinal lymph nodes.13 In 502 patients, 572 lymph nodes
were punctured using EBUS-TBNA resulting in a confirmed
diagnoses for 535 lymph nodes (94%). The sensitivity was
94%, and the specificity was 100%.
In an International Association for the Study of Lung
Cancer study of more than 67,000 patients,17 Rusch et al.5
reported that survival varied by the number of involved nodal
zones. Patients with a single N1 node had significantly better
survival than did those with either multiple N1 nodes or single
N2 node, and multiple N2 nodes were associated with a dis-
tinctly worse prognosis. These findings suggest that prognosis is
affected by disease burden as well as by the anatomic location
of involved lymph nodes.
These findings imply that proper anatomic staging of
regional hilar nodes may be more important than assumed
and that trials evaluating different therapeutic strategies for
these patients may be warranted. If more detailed hilar eval-
uation will be required more often, then EBUS-TBNA is
ideally suited for that task. Surgical approaches usually re-
quire video-assisted thoracoscopic surgery or thoracotomy
and are reasonable for patients undergoing pulmonary resec-
tion, but obviously would play a lesser role for preresection
staging. Endoscopic ultrasound-guided fine-needle aspiration
although of excellent utility for central nodes does not reli-
ably reach hilar nodal stages. EBUS-TBNA is a minimally
invasive procedure that affords excellent access to the hilar
stations and in this trial, we could show that, it has excellent
performance characteristics not only in just identifying ma-
lignant involvement but also in the differentiation of the
number of affected lymph node stations.
TABLE 1. Reasons of Exclusion of the Final Analysis (25 of
213 Patients) Based on the Final Diagnosis
Small cell lung cancer 12
Sarcoidosis 5
Tuberculosis 2
Crytogenic organising pneumonia 2
Refused surgery 2
Distant metastasis 2
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Limitations of the Study
EBUS-TBNA is an operator-dependent technique. All
procedures in this study were performed by experienced
bronchoscopists skilled in using EBUS. Further studies with
more operators and centers will be necessary to establish the
usefulness of the technique in routine practice.
CONCLUSIONS
In experienced hands, EBUS-TBNA of enlarged hilar
lymph visible on CT or PET scans can provide diagnostic
results similar to those for central mediastinal nodes.
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